Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADX-10061
- Development stage
- Discontinued
- Lead developer
- Addex Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ADX‑10061 is a potent, selective small molecule antagonist of the dopamine D1 receptor. It was originally developed by Novo Nordisk and later by Addex Pharmaceuticals for potential use in treating nicotine dependence (smoking cessation), schizophrenia, sleep disorders, and other substance-related disorders. The drug acts as a competitive orthosteric antagonist at the dopamine D1 receptor, which is implicated in reward-seeking behaviors and cue-induced craving—mechanisms fundamental to addiction. Despite reaching Phase II clinical trials for several indications, development was discontinued after failing to demonstrate efficacy in smoking cessation trials. The compound has also been used as a research tool to study dopaminergic function in the brain[1][2][3][5][6].
- Other names
- ADX10061ADX-10061ADX 10061
02
Targets
DRD1 (Dopamine D1 Receptor)AC (Adenylyl cyclase family)
Beyond the preview
Go deeper on ADX-10061.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADX-10061.